With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33454-82-9,Lithium trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.
The mixture of 1 (1.11 g, 4.3 mmol) and LiOTf (0.81 g, 5.1 mmol) in dryCH3CN was stirred at room tempareture. After stirring 18 h, the reaction mixturewas diluted with CH2Cl2. Filteration and removal of solvent under reducedpuressure afforded IL-tag 2 as a white solid in 88% yield (1.41 g, 3.8 mmol).(4-(hydroxymethyl)benzyl)methylpiperidinium trifluoromethane sulfonate(2). TLC (MeOH/CH3COOH 10:1): Rf 0.39. 1H NMR (MeOD-d4, 600 MHz)delta 7.56 (d, J = 8.4 Hz, 2 H), 7.53 (d, J = 8.4 Hz, 2 H), 4.70 (s, 2 H), 4.57 (s, 2 H),3.43 (td, J = 13.2, 4.2 Hz, 2 H), 3.36 (dt, J = 12.6, 4.2 Hz, 2 H), 3.00 (s, 3 H),2.05 – 1.94 (m, 4 H), 1.83 – 1.78 (m, 1 H) , 1.71 – 1.64 (m, 1 H). 13C NMR(MeOD-d4, 150 MHz) delta 146.0, 134.2, 128.4, 127.1, 121.9 (q, J = 316.4 Hz), 68.9,64.4, 61.9, 47.2, 22.2, 21.1. HRMS (ESI) m/z calcd for C14H22NO [M-TfO-]+,220.1696; found, 220.1688.
33454-82-9, 33454-82-9 Lithium trifluoromethanesulfonate 3664839, acatalyst-ligand compound, is more and more widely used in various fields.
Reference£º
Article; Sasaki, Norihiko; Nokami, Toshiki; Itoh, Toshiyuki; Chemistry Letters; vol. 46; 5; (2017); p. 683 – 685;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI